Company intelligence / Profile preview
Hefei Cosource Pharmaceutical
Hefei, Anhui, Chinaheyuanpharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Hefei Cosource Pharmaceutical is a private Chinese pharmaceutical company focused on the research, development, and production of innovative drugs—primarily small molecules—for oncology, cardiovascular, hematological, and nervous system diseases. Its lead asset is HYML‑122 for FLT3-positive acute myeloid leukemia in Phase 2 trials. Other assets include sabarubicin hydrochloride for refractory small cell lung cancer and HYC‑11395 for thrombosis in early clinical stages. The company also provides integrated R&D services including synthesis techniques, safety assessment, pharmacokinetics studies, and clinical trial support.
- Therapeutic areas
- CardiovascularOncology
- Modalities
- Small molecule drug
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Fruithy Medical Pty Ltd
Beyond the preview
Go deeper on Hefei Cosource Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hefei Cosource Pharmaceutical.